{"id":687983,"date":"2022-09-22T08:05:58","date_gmt":"2022-09-22T12:05:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"modified":"2022-09-22T08:05:58","modified_gmt":"2022-09-22T12:05:58","slug":"onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","title":{"rendered":"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEWTOWN, Pa., Sept.  22, 2022  (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY.<\/p>\n<p align=\"justify\">Steven Fruchtman, M.D., President &amp; CEO of Onconova, will present a corporate overview to include an update on the company\u2019s portfolio, followed by a 10-minute analyst-led fireside chat, on September 29<sup>th<\/sup>, 2022, at 12:00 p.m. ET. The presentation can be viewed <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-tmBM2aIF6djFTAu0O6U6uHf28X34O180F0EteJVsA0pLVDJBPDJKMaB-l9rgKn0PnKYUG8AUDHiXwD8YIOAmpF-2GPBDwtFPXvJcoxK7cg=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a> or on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J0gOVwxHYS52uro3Moz2aq3kpxd3iZMPIy5gRwwjxTwqbUQuZZlG3rvRQ3rqLzmeepaXo7UwmOO8xaKFyg9qyyX7uYV5vMNOywvlJmbab1eM0G3lRNVkOV-fIGhgVDeGh9y3CYlo0xseFliQOkz6Ew==\" rel=\"nofollow noopener\" target=\"_blank\">Corporate Events and Presentations<\/a>\u201d section of the Onconova website and will be archived for 90 days. Dr. Fruchtman and other members of the Onconova management team will also be available for in-person one-on-one meetings during the conference on September 29<sup>th<\/sup>, 2022. Those interested in requesting a meeting should contact their Ladenburg Thalmann representative.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>About Onconova Therapeutics, Inc. <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.<\/p>\n<p align=\"justify\">Onconova\u2019s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.<\/p>\n<p align=\"justify\">Onconova\u2019s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1\/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SCMMx-NFe2IIhHpqgm_jrB_-SN-7qoV0f1CCKiZelO4btPw0Wq6YONIh9oVvTuxFJddBl61fl20UocSOVDAeJDxRL0XpTDgrKZmF8iVQBy1_95KguIUAErAAStNfC9WFvu7uMnThF7c14AfA53kPVCaABwIRvsDi_EeKk9IvrVDqi2HmfIvVppiZVLg5k3R0DMJqPhmx8rLocC5xHMdZZQiJ-FmvHInZ2XOUS2xTpGM=\" rel=\"nofollow noopener\" target=\"_blank\">www.onconova.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Mark Guerin<br \/>Onconova Therapeutics, Inc.<br \/>267-759-3680<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BR-fV-SQadX8mRMY2M0UDYx6LmfSXx5hQxrfWg55o5vvPFYU2QBppUSwSHUqSHyC4sFGKYU_0jS4ox1DaZnISg==\" rel=\"nofollow noopener\" target=\"_blank\">ir@onconova.us<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-lfyIe807_XvfjkiYr_84qUDJd66W8rIwjZbwIYhF7Cxnd6mSVGc9Wx-OebxjaYAiTpbcTDgIqOc3-Rt0wb31ard5f_zDKeWj7JxHyz9yQ6KURTdpdftNg4ebVqWfwoj\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.onconova.com\/contact\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Bruce Mackle <br \/>LifeSci Advisors, LLC<br \/>646-889-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2dF2_von58mdGdeMPOznJ448EglAXOK-xwozSbxNm-mF2eSUozoGF-1jQcq7Ar40rRjMEF_0e4O9sYhcdPvA5OwJ-XTGOssPm-yYGXGQ_794UWE38Oqkjc1KVoA_hDbv\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODM5MDJjNDctNTIwZC00ZWZkLTlhZGEtYWQ1MjFhZGUxMzAyLTEwMTcxODg=\/tiny\/Onconova-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY. Steven Fruchtman, M.D., President &amp; CEO of Onconova, will present a corporate overview to include an update on the company\u2019s portfolio, followed by a 10-minute analyst-led fireside chat, on September 29th, 2022, at 12:00 p.m. ET. The presentation can be viewed here or on the \u201cCorporate Events and Presentations\u201d section of the Onconova website and will be archived for 90 days. Dr. Fruchtman &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687983","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY. Steven Fruchtman, M.D., President &amp; CEO of Onconova, will present a corporate overview to include an update on the company\u2019s portfolio, followed by a 10-minute analyst-led fireside chat, on September 29th, 2022, at 12:00 p.m. ET. The presentation can be viewed here or on the \u201cCorporate Events and Presentations\u201d section of the Onconova website and will be archived for 90 days. Dr. Fruchtman &hellip; Continue reading &quot;Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T12:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference\",\"datePublished\":\"2022-09-22T12:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\",\"name\":\"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=\",\"datePublished\":\"2022-09-22T12:05:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","og_description":"NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY. Steven Fruchtman, M.D., President &amp; CEO of Onconova, will present a corporate overview to include an update on the company\u2019s portfolio, followed by a 10-minute analyst-led fireside chat, on September 29th, 2022, at 12:00 p.m. ET. The presentation can be viewed here or on the \u201cCorporate Events and Presentations\u201d section of the Onconova website and will be archived for 90 days. Dr. Fruchtman &hellip; Continue reading \"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T12:05:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference","datePublished":"2022-09-22T12:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"wordCount":310,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","name":"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=","datePublished":"2022-09-22T12:05:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTEwMiM1MTY1NjEzIzIwMDU2MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Onconova Therapeutics to Present at the\u00a0Ladenburg Thalmann 2022 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687983"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687983\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}